Lloyd M. Segal, MBA

Lloyd is the co-founder and former President & CEO of Repare Therapeutics, a Boston and Montreal-based, clinical-stage oncology drug developer. Previously, he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor, and from 2016-2020 was an entrepreneur-in-residence with Versant Ventures in San Francisco.

He previously held CEO roles at Caprion Pharmaceticals (now CellCarta), Advanced Bioconcept and Thallion Pharmaceuticals. After serving on multiple public boards including NYSE, NASDAQ and TSX-listed entities, in 2013, Lloyd was honored by the Financial Times as Outstanding Corporate Director of the Year. His Board service includes serving as Chairman of LMC Diabetes & Endocrinology, North America’s largest community endocrinology and diabetes practice, and Chairman of MedReleaf, until its $2.5 billion sale to Aurora.

Lloyd holds a BA from Brandeis University and an MBA from Harvard Business School.